Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Medicine

Vol 9 No 1 (2024): June

Preeclampsia Management: Advancements, Guidelines, and Emerging Perspectives
Manajemen Preeklampsia: Kemajuan, Pedoman, dan Perspektif yang Muncul



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.8793
Published
June 1, 2024

Abstract

Chronic elevation in blood pressure during gestation poses a significant risk for maternal mortality, particularly in the United States. Understanding the pathophysiology of preeclampsia, a specific form of gestational hypertension, has led to developments in management strategies aimed at improving outcomes for both mothers and babies. This abstract outlines the underlying mechanisms, international guideline-based management approaches, and newer perspectives in addressing hypertension during pregnancy. The goal is to balance risks and benefits effectively, enhancing the care of pregnant women with hypertension.

Highlights:

  • Understanding the pathophysiology of preeclampsia is crucial for effective management.
  • International guidelines provide a framework for optimizing care for pregnant women with hypertension.
  • Emerging perspectives offer insights into potential advancements in treatment strategies.

Keywords: Hypertension, Preeclampsia, Eclampsia, Antihypertensive Drugs

References

  1. R.G. Sinkey, A.N. Battarbee, N.A. Bello, C.W. Ives, S. Oparil, and A.T. Tita, "Prevention, diagnosis, and management of hypertensive disorders of pregnancy: a comparison of international guidelines," Current Hypertension Reports, vol. 22, Sep. 2020.
  2. C.S. Homer, M.A. Brown, G. Mangos, and G.K. Davis, "Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension," Journal of Hypertension, vol. 26, no. 2, pp. 295-302, Feb. 2008.
  3. S.M. Billah, A.N. Khan, S.M. Rokonuzzaman, N.L. Huq, M.A. Khan, S.S. Priyanka, I.I. Mannan, S. Rahman, S. El Arifeen, and J. George, "Competency of health workers in detecting and managing gestational hypertension, pre-eclampsia, severe pre-eclampsia and eclampsia during antenatal check-ups in primary care health facilities in Bangladesh: a cross-sectional study," BMJ Open, vol. 11, no. 7, p. e046638, Jul. 2021.
  4. L. Trogstad, P. Magnus, and C. Stoltenberg, "Pre-eclampsia: Risk factors and causal models," Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 25, no. 3, pp. 329-342, Jun. 2011.
  5. F. Lu, H. Gong, H. Lei, and J. Li, "Downregulation of cathepsin C alleviates endothelial cell dysfunction by suppressing p38 MAPK/NF-κB pathway in preeclampsia," Bioengineered, vol. 13, no. 2, pp. 3019-3028, Feb. 2022.
  6. E. Jung, R. Romero, L. Yeo, N. Gomez-Lopez, P. Chaemsaithong, A. Jaovisidha, F. Gotsch, and O. Erez, "The etiology of preeclampsia," American Journal of Obstetrics and Gynecology, vol. 226, no. 2, pp. S844-S866, Feb. 2022.
  7. J.P. Granger, B.T. Alexander, W.A. Bennett, and R.A. Khalil, "Pathophysiology of pregnancy-induced hypertension," American Journal of Hypertension, vol. 14, no. S3, pp. 178S-185S, Jun. 2001.
  8. S.E. Maynard, J.Y. Min, J. Merchan, K.H. Lim, J. Li, S. Mondal, T.A. Libermann, J.P. Morgan, F.W. Sellke, I.E. Stillman, and F.H. Epstein, "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia," The Journal of Clinical Investigation, vol. 111, no. 5, pp. 649-658, Mar. 2003.
  9. N.C. Ngene and J. Moodley, "Role of angiogenic factors in the pathogenesis and management of pre-eclampsia," International Journal of Gynecology & Obstetrics, vol. 141, no. 1, pp. 5-13, Apr. 2018.
  10. S.M. Hollenberg, "Vasoactive drugs in circulatory shock," American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 7, pp. 847-855, Apr. 2011.
  11. M. A. Brown et al., "Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice," Hypertension, vol. 72, no. 1, pp. 24-43, Jul. 2018.
  12. R. Mustafa et al., "A comprehensive review of hypertension in pregnancy," J. Pregnancy, vol. 2012, Oct. 2012.
  13. D. T. Gamble et al., "Hypertensive disorders of pregnancy and subsequent cardiovascular disease: current national and international guidelines and the need for future research," Front. Cardiovasc. Med., vol. 6, p. 55, May 2019.
  14. A. Buchbinder et al., "Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia," Am. J. Obstet. Gynecol., vol. 186, no. 1, pp. 66-71, Jan. 2002.
  15. C. J. Nobles et al., "Preconception blood pressure and its change into early pregnancy: early risk factors for preeclampsia and gestational hypertension," Hypertension, vol. 76, no. 3, pp. 922-929, Sep. 2020.
  16. J. A. Hutcheon et al., "Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy," Best Pract. Res. Clin. Obstet. Gynaecol., vol. 25, no. 4, pp. 391-403, Aug. 2011.
  17. M. F. Bartal et al., "Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance," Am. J. Obstet. Gynecol., vol. 226, no. 2, pp. S819-S834, Feb. 2022.
  18. A. Tranquilli et al., "The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP," Pregnancy Hypertens., vol. 4, no. 2, pp. 97-104, Apr. 2014.
  19. L. Weinstein, "Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy," Am. J. Obstet. Gynecol., vol. 142, no. 2, pp. 159-167, Jan. 1982.
  20. M. Boushra et al., "High risk and low prevalence diseases: Eclampsia," Am. J. Emerg. Med., vol. 58, pp. 223-228, Aug. 2022.
  21. K. P. Conrad and J. M. Davison, "The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin?," Am. J. Physiol. Renal Physiol., vol. 306, no. 10, pp. F1121-F1135, May 2014.
  22. V. H. Dissanayake et al., "The urine protein heat coagulation test—a useful screening test for proteinuria in pregnancy in developing countries: a method validation study," BJOG: Int. J. Obstet. Gynaecol., vol. 111, no. 5, pp. 491-494, May 2004.
  23. I. Saxena, S. Kapoor, and R. C. Gupta, "Detection of proteinuria in pregnancy: comparison of qualitative tests for proteins and dipsticks with urinary protein creatinine index," J. Clin. Diagnostic Res., vol. 7, no. 9, pp. 1846, Sep. 2013.
  24. National High Blood Pressure Education Program, "Report of the national high blood pressure education program working group on high blood pressure in pregnancy," Am. J. Obstet. Gynecol., vol. 183, no. 1, pp. S1-S22, Jul. 2000.
  25. T. J. Yang, R. B. Sangal, and L. W. Conlon, "Eclampsia," J. Educ. Teach. Emerg. Med., vol. 6, no. 3, p. S33, Jul. 2021.
  26. J. A. Giovannitti Jr, S. M. Thoms, and J. J. Crawford, "Alpha-2 adrenergic receptor agonists: a review of current clinical applications," Anesth. Prog., vol. 62, no. 1, pp. 31-38, Mar. 2015.
  27. T. Easterling et al., "Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial," Lancet, vol. 394, no. 10203, pp. 1011-1021, Sep. 2019.
  28. M. L. Buchanan et al., "Clonidine pharmacokinetics in pregnancy," Drug Metab. Dispos., vol. 37, no. 4, pp. 702-705, Apr. 2009.
  29. T. Podymow and P. August, "Antihypertensive drugs in pregnancy," Semin. Nephrol., vol. 31, no. 1, pp. 70-85, Jan. 2011.
  30. K. Tanaka et al., "Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease," Circ. J., vol. 80, no. 10, pp. 2221-2226, Sep. 2016.
  31. N. Zitoun et al., "Prospective Evaluation of Pregnancy Outcomes after Gestational Exposure to Prazosin," Br. J. Clin. Pharmacol., Jan. 2023.
  32. I. Bellos et al., "Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis," Am. J. Obstet. Gynecol., vol. 223, no. 4, pp. 525-537, Oct. 2020.
  33. D. Churchill et al., "Diuretics for preventing pre‐eclampsia," Cochrane Database Syst. Rev., no. 1, Jan. 2007.
  34. S. Ogura, J. Suzuki, and H. Suzuki, "Antihypertensive drug therapy for women with non-severe hypertensive disorders of pregnancy: a systematic review and meta-analysis," Hypertens. Res., vol. 42, no. 5, pp. 699-707, May 2019.
  35. A. Awaludin et al., "Antihypertensive medications for severe hypertension in pregnancy: A systematic review and meta-analysis," Healthcare, vol. 10, no. 2, p. 325, Feb. 2022.
  36. P. Vigil-De Gracia et al., "Severe hypertension in pregnancy: hydralazine or labetalol: a randomized clinical trial," Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 128, no. 1-2, pp. 157-162, Sep. 2006.
  37. L. A. Magee et al., "Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis," Bmj, vol. 327, no. 7421, p. 955, Oct. 2003.
  38. J. E. Stempel et al., "Use of sodium nitroprusside in complications of gestational hypertension," Obstet. Gynecol., vol. 60, no. 4, pp. 533-538, Oct. 1982.
  39. V. Regitz-Zagrosek et al., "ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)," Eur. Heart J., vol. 32, no. 24, pp. 3147-3197, Dec. 2011.
  40. M. L. Costa, R. D. Cavalli, H. A. Korkes, E. V. Cunha Filho, and J. C. Peraçoli, "Diagnosis and management of preeclampsia: suggested guidance on the use of biomarkers," Revista Brasileira de Ginecologia e Obstetricia/RBGO-Gynecology and Obstetrics, vol. 44, no. 09, pp. 878-883, Apr. 2022.
  41. J. N. Martin Jr, B. D. Thigpen, R. C. Moore, C. H. Rose, J. Cushman, and W. May, "Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure," Obstetrics & Gynecology, vol. 105, no. 2, pp. 246-254, Feb. 2005.
  42. A. C. Levin, P. L. Doering, and R. C. Hatton, "Use of nifedipine in the hypertensive diseases of pregnancy," Annals of Pharmacotherapy, vol. 28, no. 12, pp. 1371-1378, Dec. 1994.
  43. A. Rosen, M. Klein, and A. Beck, "Follow-up in HELLP syndrome," Zentralblatt fur Gynakologie, vol. 112, no. 5, pp. 273-277, Jan. 1990.
  44. R. Nirupama et al., "Preeclampsia: Pathophysiology and management," Journal of Gynecology Obstetrics and Human Reproduction, vol. 50, no. 2, p. 101975, Feb. 2021.
  45. Q. A. Shahzad Qamar et al., "A review on the clinical pharmacokinetics of hydralazine," Expert Opinion on Drug Metabolism & Toxicology, vol. 18, no. 10, pp. 707-714, Oct. 2022.
  46. G. M. Peres, M. Mariana, and E. Cairrão, "Pre-eclampsia and eclampsia: An update on the pharmacological treatment applied in Portugal," Journal of Cardiovascular Development and Disease, vol. 5, no. 1, p. 3, Jan. 2018.
  47. S. Shekhar et al., "Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta‐analysis," BJOG: An International Journal of Obstetrics & Gynaecology, vol. 123, no. 1, pp. 40-47, Jan. 2016.
  48. L. Duley et al., "Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia," Cochrane Database of Systematic Reviews, no. 11, Nov. 2010.
  49. G. M. Kassie, D. Negussie, and J. H. Ahmed, "Maternal outcomes of magnesium sulphate and diazepam use in women with severe pre-eclampsia and eclampsia in Ethiopia," Pharmacy Practice, vol. 12, no. 2, Apr. 2014.
  50. A. Jagoda and S. Riggio, "Emergency department approach to managing seizures in pregnancy," Annals of Emergency Medicine, vol. 20, no. 1, pp. 80-85, Jan. 1991.
  51. L. Duley et al., "Antiplatelet agents for preventing pre‐eclampsia and its complications," Cochrane Database of Systematic Reviews, no. 10, Oct. 2019.
  52. J. M. Roberts et al., "Vitamins C and E to prevent complications of pregnancy-associated hypertension," New England Journal of Medicine, vol. 362, no. 14, pp. 1282-1291, Apr. 2010.
  53. S. F. Olsen et al., "Duration of pregnancy in relation to fish oil supplementation and habitual fish intake: a randomised clinical trial with fish oil," European Journal of Clinical Nutrition, vol. 61, no. 8, pp. 976-985, Aug. 2007.
  54. M. Zulfeen, R. Tatapudi, and R. Sowjanya, "IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy–A randomized controlled trial," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 236, pp. 46-52, May 2019.
  55. T. Easterling et al., "Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial," The Lancet, vol. 394, no. 10203, pp. 1011-1021, Sep. 2019.
  56. S. Shekhar et al., "Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial," Obstetrics & Gynecology, vol. 122, no. 5, pp. 1057-1063, Nov. 2013.
  57. J. A. Adebayo et al., "Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: A randomised controlled trial," Nigerian Postgraduate Medical Journal, vol. 27, no. 4, pp. 317-324, Oct. 2020.

Downloads

Download data is not yet available.